TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.

D Ross Camidge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.